Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher's disease, Biochemical and Biophysical Research Communications, vol.18, issue.2, pp.221-225, 1965. ,
DOI : 10.1016/0006-291X(65)90743-6
Immunochemical Characterization of Two Activator Proteins Stimulating Enzymic Sphingomyelin Degradation in vitro Absence of One of them in a Human Gaucher Disease Variant, Biological Chemistry Hoppe-Seyler, vol.367, issue.2, pp.879-890, 1986. ,
DOI : 10.1515/bchm3.1986.367.2.879
Molecular and cell biology of acid ??-glucosidase and prosaposin, Prog Nucleic Acid Res Mol Biol, vol.66, pp.203-239, 2001. ,
DOI : 10.1016/S0079-6603(00)66030-0
Type 2 Gaucher disease: 15 new cases and review of the literature, Brain and Development, vol.28, issue.1, pp.39-48, 2006. ,
DOI : 10.1016/j.braindev.2005.04.005
Recent clinical progress in Gaucher disease, Current Opinion in Pediatrics, vol.17, issue.4, pp.519-524, 2005. ,
DOI : 10.1097/01.mop.0000172702.33128.19
5 Neuronopathic forms of Gaucher's disease, Bailli??re's Clinical Haematology, vol.10, issue.4, pp.711-723, 1997. ,
DOI : 10.1016/S0950-3536(97)80035-2
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study, Clinical Genetics, vol.146, issue.12, pp.430-440, 2008. ,
DOI : 10.1111/j.1399-0004.2008.00978.x
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease., Journal of Clinical Investigation, vol.93, issue.3, pp.1288-1292, 1994. ,
DOI : 10.1172/JCI117084
Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease, Blood Cells, Molecules, and Diseases, vol.35, issue.2, pp.259-267, 2005. ,
DOI : 10.1016/j.bcmd.2005.05.005
Elevation of Serum Angiotensin-Converting Enzyme in Gaucher's Disease, New England Journal of Medicine, vol.294, issue.26, pp.1442-1444, 1976. ,
DOI : 10.1056/NEJM197606242942609
Gaucher Disease, Medicine, vol.71, issue.6, pp.337-353, 1992. ,
DOI : 10.1097/00005792-199211000-00002
Serum ferritin concentration in Gaucher's disease., BMJ, vol.286, issue.6381, p.1864, 1983. ,
DOI : 10.1136/bmj.286.6381.1864
Elevation of serum acid phosphatase in Gaucher's disease, J Mt Sinai Hosp N Y, vol.23, pp.227-229, 1956. ,
Tartrate-resistant acid phosphatase staining of monocytes in gaucher disease, American Journal of Hematology, vol.80, issue.3, pp.237-244, 1985. ,
DOI : 10.1002/ajh.2830190305
Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy, Clinica Chimica Acta, vol.344, issue.1-2, pp.101-107, 2004. ,
DOI : 10.1016/j.cccn.2004.02.018
Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease, Acta Paediatrica, vol.24, issue.2, pp.7-14, 2008. ,
DOI : 10.1016/j.ymgme.2006.04.013
Correlation of Bone Marrow Response with Hematological, Biochemical, and Visceral Responses to Enzyme Replacement Therapy of Nonneuronopathic (Type 1) Gaucher Disease in 30 Adult Patients, Blood Cells, Molecules, and Diseases, vol.28, issue.2, pp.209-220, 2002. ,
DOI : 10.1006/bcmd.2002.0511
Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients, Seminars in Hematology, vol.41, pp.4115-4137, 2004. ,
DOI : 10.1053/j.seminhematol.2004.07.010
Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002, HIV Medicine, vol.36, issue.3, pp.198-205, 1996. ,
DOI : 10.1002/hep.510300409
Disease System Analysis: Basic Disease Progression Models in Degenerative Disease, Pharmaceutical Research, vol.45, issue.7, pp.1038-1049, 2005. ,
DOI : 10.1007/s11095-005-5641-5
A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus, Journal of Pharmacokinetics and Pharmacodynamics, vol.108, issue.8, pp.313-343, 2006. ,
DOI : 10.1007/s10928-006-9008-2
Evaluation of three biochemical markers in the monitoring of Gaucher disease, Journal of Inherited Metabolic Disease, vol.28, issue.4, pp.585-592, 2005. ,
DOI : 10.1007/s10545-005-0585-9
Serum chitotriosidase activity in gaucher patients on enzyme replacement therapy (ERT), Clinical Biochemistry, vol.31, issue.5, pp.417-420, 1998. ,
DOI : 10.1016/S0009-9120(98)00030-7
36. Dose???response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type I, Molecular Genetics and Metabolism, vol.93, issue.2, pp.92-100, 2009. ,
DOI : 10.1016/j.ymgme.2007.10.048
Beta-glucosidase assays in the diagnosis of Gaucher's disease, Clin Chem, vol.28, pp.569-577, 1982. ,
4 Plasma and metabolic abnormalities in Gaucher's disease, Bailli??re's Clinical Haematology, vol.10, issue.4, pp.691-709, 1997. ,
DOI : 10.1016/S0950-3536(97)80034-0
The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease, Clinical Genetics, vol.104, issue.Suppl. 1, pp.205-211, 2007. ,
DOI : 10.1111/j.1399-0004.2007.00769.x
Timing of initiation of enzyme replacement therapy after diagnosis of type 1 ,
Age dependency of serum acid phosphatase in controls and Gaucher patients, Enzyme, vol.32, pp.95-99, 1984. ,